BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.Peer-Reviewed Original ResearchConceptsTumor-initiating cellsProstate tumor-initiating cellsBmi-1Androgen receptor-directed therapyIntrinsic therapy resistanceReceptor-directed therapyProstate cancer managementProstate cancer treatmentMore effective therapiesBmi-1 expressionProstate cancer cellsStem cell-like traitsSelf-renewing tumor-initiating cellsCell-like traitsPatient-derived cellsEffective therapyTumor relapseCancer managementXenograft modelTherapy resistancePharmacologic inhibitionBmi-1 functionTherapyNormal tissuesCancer treatmentPersonalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 64. PMID: 27446916, PMCID: PMC4917534, DOI: 10.3389/fcell.2016.00064.Peer-Reviewed Original ResearchProstate cancerTumor initiating cellsHuman immune systemHumanized miceTherapeutic responsePersonalized therapeutic responseAdaptive T cellsPrimary prostate cancerPatient-derived organoidsPersonalized medicine approachPCa microenvironmentSelective engraftmentImmunotherapy approachesCommon malignancyCancer deathSpecific therapyImmune cellsDisease progressionCancer precision medicineCommon causeT cellsChimeric antigenPatient-specific therapiesMouse modelTherapy resistance